Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization.[ Read More ]
The intrinsic value of one AMGN stock under the base case scenario is HIDDEN Compared to the current market price of 284 USD, Amgen Inc. is HIDDEN
Current Assets | 30.3 B |
Cash & Short-Term Investments | 10.9 B |
Receivables | 7.94 B |
Other Current Assets | 11.4 B |
Non-Current Assets | 66.8 B |
Long-Term Investments | 0 |
PP&E | 6.59 B |
Other Non-Current Assets | 60.2 B |
Current Liabilities | 18.4 B |
Accounts Payable | 1.59 B |
Short-Term Debt | 1.56 B |
Other Current Liabilities | 15.2 B |
Non-Current Liabilities | 72.5 B |
Long-Term Debt | 63.9 B |
Other Non-Current Liabilities | 8.67 B |
Revenue | 28.2 B |
Cost Of Revenue | 8.45 B |
Gross Profit | 19.7 B |
Operating Expenses | 11.9 B |
Operating Income | 7.9 B |
Other Expenses | 1.18 B |
Net Income | 6.72 B |
Net Income | 6.72 B |
Depreciation & Amortization | 4.07 B |
Capital Expenditures | -1.11 B |
Stock-Based Compensation | 431 M |
Change in Working Capital | -484 M |
Others | -1.56 B |
Free Cash Flow | 7.36 B |
Date | Value | Insider | Amount | Avg Price |
---|---|---|---|---|
6 months ago
May 03, 2024
|
Sell 663 K USD
|
Grygiel Nancy A.
SVP & CCO |
- 2117
|
313.0853 USD |
11 months ago
Dec 04, 2023
|
Sell 572 K USD
|
Grygiel Nancy A.
SVP & CCO |
- 2096
|
273.0323 USD |
1 year ago
Nov 08, 2023
|
Sell 2.73 M USD
|
Graham Jonathan P
EVP, Gen. Counsel & Secy. |
- 10000
|
272.8136 USD |
1 year ago
Aug 10, 2023
|
Sell 2.51 M USD
|
Gordon Murdo
EVP, Global Commercial Ops |
- 9558
|
262.43 USD |
2 years ago
Nov 09, 2022
|
Sell 113 K USD
|
Khosla Rachna
SVP, Business Development |
- 387
|
292.9 USD |
2 years ago
Nov 08, 2022
|
Sell 160 K USD
|
Grygiel Nancy A.
SVP & CCO |
- 545
|
293.535 USD |
2 years ago
Aug 22, 2022
|
Sell 50 K USD
|
Williams R Sanders
director: |
- 200
|
249.96 USD |
2 years ago
Aug 18, 2022
|
Sell 1.64 M USD
|
ECKERT ROBERT
director: |
- 6600
|
248.9966 USD |
2 years ago
May 23, 2022
|
Sell 150 K USD
|
Williams R Sanders
director: |
- 600
|
250 USD |
2 years ago
May 10, 2022
|
Sell 3.26 M USD
|
Graham Jonathan P
EVP, Gen. Counsel & Secy. |
- 13500
|
241.8114 USD |
3 years ago
May 12, 2021
|
Sell 251 K USD
|
SUGAR RONALD D
Director |
- 1000
|
250.59 USD |
3 years ago
May 11, 2021
|
Sell 631 K USD
|
Grygiel Nancy A.
SVP & CCO |
- 2500
|
252.5089 USD |
3 years ago
May 07, 2021
|
Sell 62.9 K USD
|
Williams R Sanders
Director |
- 250
|
251.78 USD |
3 years ago
Apr 14, 2021
|
Sell 250 K USD
|
SUGAR RONALD D
Director |
- 1000
|
249.98 USD |
3 years ago
Mar 10, 2021
|
Sell 232 K USD
|
SUGAR RONALD D
Director |
- 1000
|
231.53 USD |
3 years ago
Feb 10, 2021
|
Sell 238 K USD
|
SUGAR RONALD D
Director |
- 1000
|
238.4 USD |
3 years ago
Feb 08, 2021
|
Sell 59.5 K USD
|
Williams R Sanders
Director |
- 250
|
237.99 USD |
3 years ago
Feb 04, 2021
|
Sell 2.63 M USD
|
Graham Jonathan P
EVP, Gen. Counsel & Secy. |
- 11110
|
236.5099 USD |
3 years ago
Jan 13, 2021
|
Sell 236 K USD
|
SUGAR RONALD D
Director |
- 1000
|
235.99 USD |
4 years ago
Nov 09, 2020
|
Sell 60.6 K USD
|
Williams R Sanders
Director |
- 250
|
242.4 USD |
4 years ago
Aug 19, 2020
|
Sell 241 K USD
|
SUGAR RONALD D
Director |
- 1000
|
241.02 USD |
4 years ago
Aug 07, 2020
|
Sell 60.7 K USD
|
Williams R Sanders
Director |
- 250
|
242.95 USD |
4 years ago
Jul 22, 2020
|
Sell 260 K USD
|
SUGAR RONALD D
Director |
- 1000
|
259.79 USD |
4 years ago
Jun 17, 2020
|
Sell 229 K USD
|
SUGAR RONALD D
Director |
- 1000
|
228.54 USD |
4 years ago
May 20, 2020
|
Sell 229 K USD
|
SUGAR RONALD D
Director |
- 1000
|
229.27 USD |
4 years ago
May 06, 2020
|
Sell 101 K USD
|
Williams R Sanders
Director |
- 425
|
237.31 USD |
4 years ago
Apr 22, 2020
|
Sell 233 K USD
|
SUGAR RONALD D
Director |
- 1000
|
233.35 USD |
4 years ago
Feb 06, 2020
|
Sell 99.3 K USD
|
Williams R Sanders
Director |
- 425
|
233.72 USD |
4 years ago
Feb 06, 2020
|
Sell 2.13 M USD
|
Piacquad David
SVP, Business Development |
- 9264
|
229.9308 USD |
4 years ago
Nov 25, 2019
|
Sell 2.05 M USD
|
Meline David W
EVP & CFO |
- 8737
|
234.36 USD |
4 years ago
Nov 22, 2019
|
Sell 2.07 M USD
|
Graham Jonathan P
EVP, Gen. Counsel & Secy. |
- 9000
|
230.5374 USD |
5 years ago
Nov 06, 2019
|
Sell 91.6 K USD
|
Williams R Sanders
Director |
- 425
|
215.45 USD |
5 years ago
Nov 06, 2019
|
Sell 431 K USD
|
SUGAR RONALD D
Director |
- 2000
|
215.45 USD |
5 years ago
Oct 02, 2019
|
Sell 387 K USD
|
SUGAR RONALD D
Director |
- 2000
|
193.58 USD |
5 years ago
Sep 04, 2019
|
Sell 413 K USD
|
SUGAR RONALD D
Director |
- 2000
|
206.7 USD |
5 years ago
Aug 30, 2019
|
Sell 598 K USD
|
Patton Cynthia M
SVP & CCO |
- 2875
|
208.0672 USD |
5 years ago
Aug 30, 2019
|
Sell 999 K USD
|
Patton Cynthia M
SVP & CCO |
- 4802
|
208.0672 USD |
5 years ago
Aug 07, 2019
|
Sell 77.8 K USD
|
Williams R Sanders
Director |
- 425
|
183.04 USD |
5 years ago
Aug 07, 2019
|
Sell 366 K USD
|
SUGAR RONALD D
Director |
- 2000
|
183.04 USD |